FSD Pharma

FSD Pharma, Inc. is a specialty biotech pharmaceutical research and development company. It focuses on developing over time a robust pipeline of FDA-approved synthetic compounds targeting the end cannabinoid system of the human body to treat certain diseases of the central nervous system and autoimmune disorders of the skin, GI tract, and the musculoskeletal system. The company was founded by Thomas Fairfull, Zeeshan Saeed and Anthony J. Durkacz on October 20, 1994 and is headquartered in Toronto, Canada.

Earnings data Q3 2020

Earnings data Q4 2020

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Quantum Biopharma Ltd. is a biotechnology pharmaceutical research and development company, which focuses on the cultivation, process, and sale of medical cannabis. It operates through the Biotechnology and Strategic Investments segments. The Biotechnology segment is involved in the research and development of the company's three drug candidates consisting of FSD-PEA, Lucid-PSYCH, and Lucid-MS. The Strategic Investments segment is focused on generating returns and cashflow through the issuance of loans secured by residential or commercial property. The company was founded by Thomas Fairfull, Zeeshan Saeed and Anthony J. Durkacz on October 20, 1994 and is headquartered in Toronto, Canada.

TORONTO, Oct. 13, 2021 /PRNewswire/ -- FSD Pharma Inc. (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9) ("FSD Pharma" or the "Company"), a life sciences holding company dedicated to building a portfolio of assets and biotech solutions, is pleased to announce that Anthony Durkacz, Interim CEO of FSD Pharma, and Dr. Lakshmi P. Kotra, CEO of FSD's wholly-owned subsidiary Lucid Psycheceuticals, will participate in the KCSA Psychedelics Investor Conference to be held at VirtualInvestorConferences.com on October 13-14, 2021.

FSD Pharma to Present at the KCSA Psychedelics Virtual Investor Conference on October 13th

TORONTO--(BUSINESS WIRE)---- $HUGE #RestoreFSD--FSD Pharma Inc. (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9) (“FSD Pharma” or the “Company”), a life sciences holding company dedicated to building a portfolio of assets and biotech solutions, announced today it has retained the services of Hybrid Financial Ltd. (“Hybrid”), North Equities Corp. (the "North Equities"), Looking Glass Capital Consultants (“Looking Glass”), Worldwide Media Solutions, LLC (“BGTV Direct”), KCSA Strategic Communications ("KCSA"), and Digi Messaging

FSD Pharma Announces Engagement with Capital Markets Communications Providers and Market Maker

FSD Pharma Inc said it has completed its previously-announced acquisition of Canadian psychedelic pharmaceutical company Lucid Psycheceuticals Inc for about C$11.3 million in FSD Pharma stock. FSD Pharma said the acquisition provides it with new assets at the forefront of new medicine and represented a 'paradigm shift' in its development.

FSD Pharma closes its all-stock acquisition of Canada's Lucid Psycheceuticals

TORONTO--(BUSINESS WIRE)---- $HUGE #RestoreFSD--FSD Pharma Inc. (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9) (“FSD Pharma” or the “Company”), a life sciences holding company dedicated to building a portfolio of assets and biotech solutions, is pleased to announce the completion of the previously announced acquisition of 100% of the issued and outstanding shares of Lucid Psycheceuticals Inc. (“Lucid”), a Canadian-based specialty psychedelic pharmaceutical company focused on the development of therapies to treat critical neu

FSD Pharma Announces Closing of Lucid Psycheceuticals Acquisition

FSD Pharma Inc. (NASDAQ:HUGE) (CSE:HUGE), a life sciences holding company looking at cannabinoid and psychedelic-based medicines, announced it is entering a definitive agreement to acquire Lucid Psycheceuticals Inc.  Lucid is a psychedelic pharmaceutical company focused on developing therapies to treat neurodegenerative diseases and mental health disorders.

Nasdaq-listed FSD Pharma To Advance Psychedelics Pipeline With $9 Million Acquisition Of Lucid Psycheceuticals

FSD Pharma Inc (NASDAQ: HUGE) shares rebounded after falling in premarket on acquiring a Canada-based psychedelic pharmaceutical company. Related:   See Why FSD Pharma Terminated COVID-19 Trial

FSD Pharma To Buy Canadian Psychedelic Pharmaceutical Firm

FSD Pharma Inc is to buy Canada-based specialty psychedelic pharma group Lucid Psycheceuticals Inc in a stock deal worth around US$9 million (C$11.3 million).  The life sciences holding company said the acquisition provided it with new assets at the forefront of new medicine and represented a 'paradigm shift' in its development.

FSD Pharma to buy pharma group Lucid Psycheceuticals in a stock deal worth US$9 million

Acquisition Advances Company's Strategic Plan Toward a Diversified Novel Drug Development Pipeline in Psychedelics and Medical Cannabis Acquisition Advances Company's Strategic Plan Toward a Diversified Novel Drug Development Pipeline in Psychedelics and Medical Cannabis

FSD Pharma Announces Definitive Agreement to Acquire Lucid Psycheceuticals

FSD Pharma Inc (NASDAQ: HUGE) will terminate the Phase 2 trial of ultra-micronized palmitoylethanolamide (PEA), or FSD-201, for COVID-19. FSD-201 works by stabilizing mast cells and down-regulates the pro-inflammatory cytokines to effectuate an anti-inflammatory response.

See Why FSD Pharma Terminated COVID-19 Trial

TORONTO--(BUSINESS WIRE)--FSD Pharma Inc. (Nasdaq:HUGE) (CSE:HUGE) (FRA:0K9) (the “Company” or “FSD”) announced today that it intends to terminate the Phase 2 clinical trial of ultra-micronized palmitoylethanolamide ("PEA"), or FSD-201, for use in treating COVID-19. FSD-201 stabilizes mast cells and down-regulates the pro-inflammatory cytokines to effectuate an anti-inflammatory response; it is also known to target the CB2 receptors of the endocannabinoid system of the human body. The Company h

FSD Pharma Inc. Announces Termination of FSD-201 Phase 2 Clinical Trial

FSD Pharma Inc has announced the appointment of Anthony Durkacz as the company's new interim chief executive officer (CEO) as well as the reinstatement of Zeeshan Saeed as FSD Pharma's president. Durkacz had previously served on FSD Pharma's board of directors as its co-chairman.

FSD Pharma appoints Anthony Durkacz as its new interim chief executive officer

TORONTO--(BUSINESS WIRE)---- $HUGE #RestoreFSD--FSD Pharma Inc. (Nasdaq: HUGE) (CSE:HUGE) (FRA:0K9) (the “Company” or “FSD”) announced today that the board of directors had terminated the employment of the Company's Chief Executive Officer, Dr. Raza Bokhari for cause. As previously disclosed by the Company, Dr. Bokhari was placed on administrative leave following the Company's shareholder meeting on May 14, 2021 while a special committee (the “Special Committee”) comprised of two independent directors investigated v

FSD Pharma Inc. Announces Termination of Chief Executive Officer Dr. Raza Bokhari for Cause

Aurora Cannabis

Applied DNA Sciences

Arena Pharmaceuticals

Canopy Growth

HEXO Corp

Neptune Wellness Solutions Inc.

OrganiGram Holdings Inc.

SNDL Inc.

Tilray Brands

cbdMD Inc

Welcome back to our weekly series, Schaeffer's Cannabis Stock News Update, where we recap what happened in the world of marijuana stocks last week and look ahead to how the cannabis industry continues to take shape in 2021.

Breaking Down a Busy Week of Weed Stocks

FSD Pharma Inc (NASDAQ:HUGE) (CSE:HUGE) (FRA:0K9) announced it has appointed Adnan Bashir as an independent member of the company's board of directors. Bashir, a former general manager of Dubai-based business conglomerate Al Batha group, has more than 14 years of experience in strategic management and operations.

FSD Pharma appoints Adnan Bashir as an independent company director

TORONTO--(BUSINESS WIRE)---- $HUGE #HUGE--FSD Pharma Inc. (Nasdaq: HUGE) (CSE:HUGE) (FRA:0K9) (the “Company” or “FSD”) is pleased to announce the appointment of Mr. Adnan Bashir as an independent member of its Board of Directors (the “Board”), upon the recommendation of the Company's Compensation, Nomination and Governance Committee. As previously announced, Mr. Frank Lavelle was elected to the Board at the Company's annual general and special meeting of shareholders held on May 14th, 2021 (the “Meeting”). Sho

FSD Pharma Inc. Appoints a New Independent Director

FSD Pharma Inc (NASDAQ:HUGE) (CSE:HUGE) (FRA:0K9) announced that the slate of board of directors nominees brought forward by a group of concerned shareholders received the necessary votes at the company's annual general and special meeting on May 14.  The nominees of the concerned group, led by Anthony Durkacz and Zeeshan Saeed, were each elected, along with Frank Lavelle and Donal Carroll, to hold office for the ensuing year.

FSD Pharma says concerned shareholder group-backed nominees elected to board at annual meeting

TORONTO--(BUSINESS WIRE)---- $HUGE #ChangeIsHappening--FSD Pharma Inc. (Nasdaq: HUGE) (CSE:HUGE) (FRA:0K9) (the “Company” or “FSD”) is pleased to announce the results of its annual general and special meeting of the shareholders held on May 14th, 2021 (the “Meeting”) at which 54.17% of the votes attached to the issued and outstanding Class B Subordinate Voting Shares (“Class B Shares”) and Class A Multiple Voting Shares (“Class A Shares”) were represented. The board of directors of FSD (the “Board”) was fixed at seven dire

FSD Pharma Inc. Announces Results of the Annual General and Special Meeting of Shareholders – Nominees of the Concerned Shareholders Elected to the Board of Directors

TORONTO--(BUSINESS WIRE)---- $HUGE--FSD Pharma Inc. (Nasdaq:HUGE) (CSE:HUGE) (the "Company" or "FSD Pharma") announced today that it has filed a criminal complaint with Toronto Police Services, Financial Crimes Unit, against Mr. Donal Carroll, the Company's former chief financial officer. The complaint asserts that Mr. Carroll has intentionally interfered with the Company's banking in order to disrupt FSD's business in the midst of an ongoing proxy contest, in alleged contravention of criminal law and Mr

FSD Pharma Announces Filing of Criminal Complaint Against Former Chief Financial Officer

Toronto, Ontario--(Newsfile Corp. - May 12, 2021) - On Monday, May 10, 2021, at the request of Messrs. Anthony Durkacz and Zeeshan Saeed, founding shareholders and members of the group of concerned shareholders (the "Concerned Shareholders") of FSD Pharma Inc. (NASDAQ: HUGE) (CSE: HUGE) (FSE: 0K9A) (the "Company" or "FSD"), the Ontario Superior Court of Justice (Commercial List) (the "Court") issued an order appointing Ms. Carol Hansell as independent chair of the Company's shareholders' meeting...

FSD Management and Board Suffers Multiple Court Losses as Shareholder Meeting Approaches

FSD Pharma Inc (NASDAQ:HUGE) (CSE:HUGE) said it has submitted to the US Food and Drug Administration an Investigational New Animal Drug Application (IND) for the use of FSD201 to treat gastrointestinal enteropathy in dogs.  The application has been accepted for review, the company added in a statement.

FSD Pharma files New Animal Drug Application with FDA for FSD201 to treat gastrointestinal enteropathy in dogs

TORONTO--(BUSINESS WIRE)---- $HUGE #DOGS--FSD Pharma Inc. (Nasdaq: HUGE) (CSE: HUGE.CN) (“FSD Pharma” or the “Company”) today announced that it has submitted to the U.S. Food and Drug Administration (“FDA”) an Investigational New Animal Drug Application (IND) for the use of FSD201 (ultramicronized palmitoylethanolamide, or ultramicronized PEA) to treat Gastrointestinal enteropathy in dogs. The application has been accepted for review. The proposed trial design is a randomized, double-blind, placebo-controlled,

FSD Pharma Announces Investigational New Animal Drug Filing With the FDA to Treat Dogs With Enteropathy

GW Pharmaceuticals

Innovative Industrial Properties

Jazz Pharmaceuticals

22nd Century Group

Welcome back to our weekly series, Schaeffer's Cannabis Stock News Update, where we recap what happened in the world of marijuana stocks last week, and look ahead to how the cannabis industry will continue to develop in 2021.

What Happened with Marijuana Stocks This Week?

TORONTO--(BUSINESS WIRE)---- $HUGE--FSD Pharma Inc. (the “Company”) today announced that Institutional Shareholder Services Inc. (“ISS”), a leading independent international corporate governance analysis and proxy advisory firm, has recommended that shareholders vote FOR all Company Director Nominees (the "Management Director Nominees") in a contested election for the Board of Directors and FOR the elimination of the dual-class share structure (the "Dual-Class Sunset") at the annual and special meeting o

FSD Pharma Announces That ISS Recommends Shareholders Vote for the Company's Nominees to the Board Using Only the BLUE Proxy

FSD Pharma Inc. (NASDAQ:HUGE) (CSE:HUGE) has announced the appointment of Nathan Coyle, the company's corporate controller as its interim chief financial officer with immediate effect, following the departure of Donal Carroll. The company noted that Coyle joined FSD Pharma as corporate controller in 2020 and has 15 years of executive business experience as a finance leader in both public and private roles.

FSD Pharma announces appointment of Nathan Coyle, the company's corporate controller as its interim chief financial officer with immediate effect

TORONTO--(BUSINESS WIRE)---- $HUGE--FSD Pharma Inc. (Nasdaq:HUGE) (CSE:HUGE) (the "Company" or "FSD Pharma") is pleased to announce the appointment of Nathan Coyle, the Company's Corporate Controller as its Interim Chief Financial Officer, following the departure of Donal Carroll, effective immediately. Mr. Coyle joined FSD Pharma Inc in 2020 as Corporate Controller and has 15 years of executive business experience as a finance leader in both public and private roles. Mr. Coyle was previously with Illino

News for FSD Pharma Stock (HUGE)